Singapore: South Korea, India, the United States, Japan, and the European Union (EU) have joined forces to establish the Biopharmaceutical Alliance, aimed at enhancing the resilience of the biopharmaceutical supply chain.
Key Points:
- Inaugural Meeting: The alliance was officially launched during the inaugural meeting held in San Diego at the Bio International Convention 2024, the world’s largest biopharmaceutical exhibition.
- Participating Countries: Representatives from government officials, bio, and pharmaceutical companies attended the meeting, emphasizing the importance of a reliable and sustainable supply chain.
- Policy Coordination: The participating nations agreed to coordinate their bio policies, regulations, and research and development support measures.
- Supply Chain Mapping: Recognizing that essential raw materials and ingredients are concentrated in a few countries, the alliance aims to create a detailed pharmaceutical supply chain map.
- COVID-19 Response: The alliance was formed in response to drug supply shortages experienced during the COVID-19 pandemic.
- Expanded Membership: Initially established by South Korea and the U.S. during their dialogue on core emerging technologies in December, the alliance has since expanded to include Japan, India, and the EU.
This collaborative effort seeks to address vulnerabilities in the biopharmaceutical supply chain, ensuring a robust and resilient system for the future.
Advertisement
